Cannabigerol

Cannabigerol (CBG) is a non-psychoactive cannabinoid that interacts with CB1 and CB2 receptors in the endocannabinoid system. Research shows CBG reduces anxiety and stress while alleviating exercise-induced muscle soreness through modulation of inflammatory pathways.

Origin & History

Cannabigerol (CBG) is a non-psychoactive phytocannabinoid and the primary precursor to other major cannabinoids in Cannabis sativa L., biosynthesized from geranyl pyrophosphate and olivetolic acid via the enzyme GSTOS. CBG accumulates in the trichomes of hemp varieties and is extracted using solvent-based methods (ethanol or CO2 supercritical extraction), followed by chromatographic isolation to achieve >98% purity for commercial use.

Historical & Cultural Context

No historical traditional use has been identified for isolated CBG, as it occurs in trace amounts (<1% in most cannabis strains) and was not isolated until 1964. While Cannabis sativa has millennia-long use in traditional Chinese, Indian Ayurvedic, and Middle Eastern medicine for pain and anxiety, CBG-specific applications are a modern development based on recent preclinical data.

Health Benefits

• Reduces anxiety and stress: In a double-blind RCT (n=34), 20mg CBG significantly reduced anxiety (p=0.04) and stress (p=0.02) without cognitive impairment
• Alleviates muscle soreness: Pilot RCT (n=40) showed moderate reduction in exercise-induced muscle soreness at 72h post-DOMS (effect estimate -1.33)
• Anti-inflammatory effects: Preclinical studies demonstrate CBG reduces NF-κB/p-NF-κB and JAK-STAT inflammatory signaling in atopic dermatitis and arthritis models
• Pain management potential: Observational survey (n=388) reported 74% of users found CBG superior to conventional medications for pain
• Sleep support: Survey data indicated 73% of users reported CBG more effective than conventional medications for insomnia

How It Works

Cannabigerol acts as a partial agonist at CB1 and CB2 cannabinoid receptors, modulating neurotransmitter release and inflammatory responses. CBG inhibits FAAH (fatty acid amide hydrolase), increasing endocannabinoid levels like anandamide. It also blocks TRPM8 channels and activates α2-adrenoreceptors, contributing to its anxiolytic and anti-inflammatory effects.

Scientific Research

Human evidence includes a double-blind, placebo-controlled crossover RCT (NCT05257044, PMID: 39003387) testing 20mg oral CBG in 34 healthy adults, demonstrating significant anxiety and stress reduction. A repeated-dose pilot RCT (NCT05026164, PMID: 37947792) in 40 adults showed moderate reduction in exercise-induced muscle soreness. No meta-analyses have been conducted to date.

Clinical Summary

A double-blind RCT with 34 participants demonstrated that 20mg CBG significantly reduced anxiety (p=0.04) and stress (p=0.02) without cognitive impairment. A separate pilot RCT (n=40) showed moderate reduction in exercise-induced muscle soreness at 72 hours post-DOMS. While these preliminary results are promising, larger studies are needed to confirm CBG's therapeutic potential. Current evidence is limited to small-scale trials with short-term outcomes.

Nutritional Profile

Cannabigerol (CBG) is a non-psychoactive cannabinoid compound, not a conventional food ingredient, and thus has no meaningful macronutrient, micronutrient, fiber, or caloric profile. It is classified as a bioactive phytocannabinoid derived primarily from Cannabis sativa L. Key compositional data: CBG is typically present in hemp/cannabis at <1% dry weight in mature plants, though selectively bred strains can yield 6–12% CBG by dry weight. As an isolated compound, it is administered in purified form (purity typically >95% in research/commercial preparations). Bioactive profile: CBG acts as a partial agonist at CB1 and CB2 endocannabinoid receptors, with higher affinity for CB2 (anti-inflammatory pathway); also interacts with TRPV1, TRPA1, and alpha-2 adrenergic receptors, and inhibits anandamide reuptake. Research dosing has been conducted at 20 mg (oral, encapsulated) in human RCTs. Bioavailability: Oral bioavailability of cannabinoids is generally low (6–19%) due to first-pass hepatic metabolism; lipid-based delivery systems (e.g., oil formulations) improve absorption. CBG is lipophilic (logP ~6.3), favoring fat-soluble matrices. It is metabolized via CYP3A4 and CYP2C9 enzymes. Half-life is estimated at 1–2 hours for oral delivery. No meaningful vitamin, mineral, protein, or fiber content is attributable to isolated CBG as a compound ingredient.

Preparation & Dosage

Clinically studied doses include 20mg single oral dose for anxiety/stress reduction and unspecified CBG-containing formulation (likely 150mg/day based on context) for 3 days in muscle soreness studies. Studies used pharmaceutical-grade isolated CBG (>98% purity) or formulations without disclosed standardization. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

CBD, CBC, CBDA, Myrcene, Limonene

Safety & Interactions

CBG appears well-tolerated in clinical studies with minimal reported side effects at doses up to 20mg daily. Potential side effects may include mild drowsiness, dry mouth, and changes in appetite based on anecdotal reports. CBG may interact with medications metabolized by cytochrome P450 enzymes, particularly CYP2C9 and CYP3A4. Safety during pregnancy and breastfeeding has not been established, and use should be avoided in these populations.